News - Vivalis, CNS Diseases

Filter

Current filters:

VivalisCNS Diseases

Popular Filters

NICE asks Biogen Idec for more information on Tecfidera

NICE asks Biogen Idec for more information on Tecfidera

21-02-2014

The UK’s National Institute for Health and Care Excellence (NICE) is calling on US biotech firm Biogen…

Biogen IdecBiotechnologyCNS DiseasesRegulationTecfideraUK

Prana reports successful Phase II results in Huntington disease trial

18-02-2014

Australia-based Prana Biotechnology has announced positive results of its Reach2HD Phase II clinical…

AustraliaBiotechnologyCNS DiseasesNeurologicalPrana BiotechnologyResearch

Forest reports third quarter sales of $846.8 million beating analysts’ expectations

Forest reports third quarter sales of $846.8 million beating analysts’ expectations

21-01-2014

US drugmaker Forest Laboratories (NYSE: FRX) released its third quarter 2013/14 results today showing…

CNS DiseasesFinancialForest LaboratoriesPharmaceuticalRespiratory and PulmonaryUSA

Forest Laboratories announces new appointments to its executive team

16-12-2013

New York-based pharmaceutical company Forest Laboratories (NYSE: FRX) has announced new appointments…

Anti-viralsBoardroomCardio-vascularCNS DiseasesForest LaboratoriesGastro-intestinalsPharmaceuticalRespiratory and PulmonaryUSA

Sativex approved for MS in Switzerland

Sativex approved for MS in Switzerland

27-11-2013

UK-based GW Pharmaceuticals (AIM: GWP), which is focused on novel cannaboid therapeutics, has received…

AlmirallCNS DiseasesEuropeGW PharmaceuticalsPharmaceuticalRegulationSativex

Collaboration agreement between French firms Vect-Horus and AAA

20-11-2013

French biotech company Vect-Horus has signed a scientific collaboration agreement with Advanced Accelerator…

Advanced Accelerator ApplicationsBiotechnologyCNS DiseasesEuropeLicensingMergers & AcquisitionsVect-Horus

GW Pharma sees fiscal 2012/3 revenues decline, impacted by Sativex

GW Pharma sees fiscal 2012/3 revenues decline, impacted by Sativex

19-11-2013

UK-based GW Pharmaceuticals (AIM: GWP) which is focused on novel cannaboid therapeutics, has announced…

CNS DiseasesFinancialGW PharmaceuticalsPharmaceuticalSativexUK

Sanofi’s Lemtrada gets support from FDA advisory panel

Sanofi’s Lemtrada gets support from FDA advisory panel

14-11-2013

French drug major Sanofi (Euronext: SAN) has received support from a US Food and Drug Administration…

CNS DiseasesEuropeGenzymeLemtradaPharmaceuticalRegulationSanofi

Novartis MS drug Gilenya leads to reduction in brain volume drug

Novartis MS drug Gilenya leads to reduction in brain volume drug

04-10-2013

Novartis has revealed new data indicating that continued treatment with Gilenya led to a reduction in…

CNS DiseasesEuropeGilenyaNovartisPharmaceuticalResearch

Inovio reveals success in DNA plasmid technology

Inovio reveals success in DNA plasmid technology

25-09-2013

US drug developer Inovio Pharmaceuticals has demonstrated the success of its new DNA plasmid technology…

Anti-Arthritics/RheumaticsBiotechnologyCNS DiseasesInovio PharmaceuticalsNorth AmericaOncologyResearch

Merger between Intercell and Vivalis planned to complete soon

14-05-2013

French biotech firm Vivalis (Euronext: VLS) previously-announced acquisition of Intercell (ICEL.VI) in…

BiotechnologyIntercellMergers & AcquisitionsVaccinesValnevaVivalis

Vivalis and Intercell announce "merger of equals"

18-12-2012

French biotech firm Vivalis (Euronext: VLS) has entered into an accord to acquire Intercell (ICEL.VI)…

BiotechnologyIntercellMergers & AcquisitionsVaccinesValnevaVivalis

Vivalis in new EB66 cell line deal with Merial

18-07-2012

France-based Vivalis (NYSE Euronext: VLS) announced today that it has executed a new research license…

EB66LicensingMerialPharmaceuticalSanofiVaccinesVivalis

Vivalis signs another EB66 out-licensing deal for MAb production

14-03-2012

French biotech firm Vivalis (NYSE Euronext: VLS) has signed a joint collaboration and commercial license…

BiotechnologyEB66LicensingVaccinesVivalis

Vivalis opens new lab for antibody discovery; posts 112% revenue hike

25-01-2012

French biotech firm Vivalis (NNYSE Euronext: VLS) says it has opened a new facility for partnered VIVA|Screen…

BiotechnologyEuropeFinancialResearchSanofi PasteurVivalis

Sanofi Pasteur and Vivalis extend MAb accord

19-01-2012

French biopharma company Vivalis (NYSE Euronext: VLS) says it has extended the agreement signed in 2010…

Antibiotics and Infectious diseasesLicensingPharmaceuticalResearchSanofiSanofi PasteurVivalis

Strong first-half 2011 for Vivalis, with net loss nearly halved

01-09-2011

French biotech firm Vivalis (Euronext Paris: VLS) has released its audited consolidated results for the…

BiotechnologyFinancialVivalis

Vivalis acquires single-cell antibody from SC World

28-04-2011

French drug firm Vivalis (Euronext: VLS) says it has acquired high-throughput screening (HTS) single-cell…

Asia-PacificLicensingPharmaceuticalSC WorldVivalis

Kaketsuken initiates second trial of flu vaccine using Vivalis EB66 cell line

26-04-2011

Japan’s Chemo-Sero-Therapeutic Research Institute (Kaketsuken) has initiated the first human injection…

GlaxoSmithKlineKaketsukenPharmaceuticalResearchRespiratory and PulmonaryVaccinesVivalis

Back to top